title: Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
authors.affiliation: From the Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (A.G.E., B.T.H., T.B., C.R.); the European Medicines Agency, London (E.B.); Läkemedelsverket, Uppsala, Sweden (K.D.); and the Dutch Medicines Evaluation Board, Utrecht, the Netherlands (P.A.G.).
authors.forename: Amy G
authors.initials: AG
authors.lastname: Egan
authors.forename: Eberhard
authors.initials: E
authors.lastname: Blind
authors.forename: Kristina
authors.initials: K
authors.lastname: Dunder
authors.forename: Pieter A
authors.initials: PA
authors.lastname: de Graeff
authors.forename: B Timothy
authors.initials: BT
authors.lastname: Hummer
authors.forename: Todd
authors.initials: T
authors.lastname: Bourcier
authors.forename: Curtis
authors.initials: C
authors.lastname: Rosebraugh
mesh_terms: D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D017277:Drug Approval; D004353:Drug Evaluation, Preclinical; D005062:European Union; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D054795:Incretins / Q000009:adverse effects*; D051379:Mice; D010190:Pancreatic Neoplasms / Q000139:chemically induced*; D010195:Pancreatitis / Q000139:chemically induced*; D051381:Rats; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007004:Hypoglycemic Agents; D054795:Incretins